LD-2 disclosure · 3rd Quarter - Report
GENZYME CORPORATION
Client
- Location
- District of Columbia · United States of America
Registrant
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
5 issuesBudget/Appropriations
FY 2013 Budget FY 2014 Budget FY 2013 Appropriations - Labor-HHS, Agriculture and FDA
Lobbyistsms KATHLEEN HOLCOMBE · SARA FROELICH
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Agency for Healthcare Research & Quality (AHRQ) · Centers For Medicare and Medicaid Services (CMS)
Medicare/Medicaid
ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013
Lobbyistsms KATHLEEN HOLCOMBE · SARA FROELICH
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS) · Agency for Healthcare Research & Quality (AHRQ) · Centers For Medicare and Medicaid Services (CMS)
